Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

4(40.0%)

Phase 2

4(40.0%)

Phase 3

2(20.0%)

10Total

Phase 1(4)

Phase 2(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03715998Phase 2Completed

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Role: lead

NCT04857840Phase 3Terminated

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

Role: lead

NCT04277884Phase 3Completed

Firibastat in Treatment-resistant Hypertension

Role: lead

NCT04792333Phase 1Completed

Pharmacokinetics in End Stage Renal Disease Patients

Role: lead

NCT03714685Phase 1Completed

Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations

Role: lead

NCT03198793Phase 2Completed

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

Role: lead

NCT02780180Phase 2Terminated

QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF

Role: lead

NCT02322450Phase 2Completed

Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension

Role: lead

NCT01900171Phase 1Completed

Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo

Role: lead

NCT01900184Phase 1Completed

Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects

Role: lead

All 10 trials loaded